Sol Barer

Sol J.
Barer is the founder of Celgene SAS, founded in 1986; Barer & Son Capital LLC, founded in 2017; Celgene Corp., founded in 1986, where the title of Executive Chairman is held from 2010 to 2011; and Centrexion Therapeutics Corp., founded in 2013, where the title of Chairman is previously held.
Current jobs include Chairman at Teva Pharmaceutical Industries Ltd. since 2017; Chairman at Medgenics Medical (Israel) Ltd.; Founding Chairman-Center for Innovation at Hackensack Meridian School of Medicine since 2018; Director at Semorex, Inc.; Director at BioNJ, Inc. since 2014; Director at PrintBio, Inc. since 2019; Director at Zephyr AI, Inc.; Trustee at Brooklyn College Foundation since 2012; Trustee at Liberty Science Center; Trustee at The Tourette Association of America since 2014; Managing Partner at SJBarer Consulting LLC since 2014; and Venture Advisor at Israel Biotech Fund.
Former jobs include Chairman at Edge Therapeutics, Inc. from 2013 to 2019; Chairman at the University of Medicine & Dentistry of New Jersey; Non-Executive Chairman at Aevi Genomic Medicine, Inc. from 2015 to 2020; Chairman at Avalo Therapeutics, Inc.; Chairman at Avalo Therapeutics, Inc. from 2020 to 2021; Non-Executive Chairman at RestorGenex Corp.
from 2015 to 2016; Chairman at NexImmune, Inc. from 2019 to 2024; Director at Cornerstone Pharmaceuticals, Inc.; Independent Director at Amicus Therapeutics, Inc. from 2011 to 2017; Independent Director at Aegerion Pharmaceuticals, Inc. from 2011 to 2016; Director at Nobex Corp.; Director at Pharmaceutical Research & Manufacturers of America; Lead Independent Director at ContraFect Corp.
from 2015 to 2023; Independent Non-Executive Director at InspireMD, Inc. in 2011; Trustee at Rutgers State University of New Jersey; and Commissioner at New Jersey Commission on Science & Technology.
Education includes an undergraduate degree from Brooklyn College conferred in 1968 and a doctorate from Rutgers State University of New Jersey conferred in 1974.